Clinical trials of transplant tolerance: Slow but steady progress

American Journal of Transplantation

Volumn 3, Issue 7, 2003, Pages 794-803

  Matthews, Jeffrey B ^a   Ramos, Eleanor ^a   Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chimerism; Clinical trials; Costimulation; T cell depletion; Tolerance

Indexed keywords

15 DEOXYSPERGUALIN; ALEFACEPT; ALEMTUZUMAB; ANTILFA; BELATACEPT; BETA1 INTEGRIN; CD28 ANTIGEN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; ODULIMOMAB; OKT 3; RAPAMYCIN; SIPLIZUMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOGRAFT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CHIMERA; CLINICAL TRIAL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; ORGAN TRANSPLANTATION; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TARGET CELL;

CHIMERA; HUMANS; IMMUNE TOLERANCE; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CELL SURFACE; TRANSPLANTATION;

EID: 0038690324     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.2003.0154.x     Document Type: Short Survey

References (87)

1. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection. J Hepatol 1998; 29: 143-150.
2. Calne RY. An opportunity in organ transplantation. Nat Med 1995; 1: 20-22.
3. Ojo AO, Meier-Kriesche H-U, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-2409.
4. Ramos HC, Reyes J, Abuelmagd K et al. Weaning of immunosuppression in long-term liver-transplant recipients. Transplantation 1995; 59: 212-217.
5. Dousset B, Hubscher SG, Padbury RT et al. Acute liver allograft rejection is treatment always necessary? Transplantation 1993; 55: 529-534.
6. Padbury RT, Gunson BK, Dousset B et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 1993; 55: 789-794.
7. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298-1302.
8. Lan F, Hayamizu K, Strober S. Cyclosporine facilitates chimeric and inhibits nonchimeric tolerance after posttransplant total lymphold irradiation. Transplantation 2000; 69: 649-655.
9. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14: 592.
10. Cosimi A. Calcineurin inhibitors are not antagonistic to tolerance induction. Transplant Proc 2002; 34: 1376-1377.
11. Millan MT, Shizuru JA, Hoffmann P et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 1386-1391.
12. Millan MT, Shizuru JA, Hoffmann P et al. Mixed chimerism and donor-specific unresponsiveness without graft-versus-host disease after MHC-mismatched hematopoietic stem cell infusion and kidney transplantation [abstract 591. Transplantation 2002; 74: 37.
13. Ferreira JV, Froud T, Caulfield A et al. Can enriched bone marrow infusion induce donor tolerance in solitary islet cell transplantation? [abstract 290] Transplantation 2002, 74.
14. Jordan MS, Riley MP, von Boehmer H, Caton AJ. Anergy and suppression regulate CD4 (+) T cell responses to a self peptide. Eur J Immunol 2000; 30: 136-144.
15. Wekerle T, Sayegh MH, Chandraker A, Swenson KG, Zhao Y, Sykes M. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc 1999; 31: 680.
16. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 System of cell costimulation. Ann Rev Immunol 1996; 14: 233-258.
17. Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 1470-1479.
18. Adams AB, Shirasugi N, Durham MM et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51: 265-270.
19. Kirk AD, Tadaki DK, Celniker A et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001; 72: 377-384.
20. Hausen B, Klupp J, Christians U et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 2001; 72: 1128-1137.
21. Vincenti F. What's in the pipeline: new immunosuppressive drugs in transplantation. Am J Transplant 2002; 2: 898-903.
22. Schopf RE. IDEC-114 (IDEC). Curr Opin Invest Drugs 2001; 2: 635-638.
23. Diabetogen press release, March 26, 2001.
24. Özkaynak E, Gao W, Shemmeri N et al. Importance of ICOS-B7RP:-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591-596.
25. Guo L, Li XK, Funeshima N et al. Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible costimulator (ICOS). Transplantation 2002; 73: 1027-1032.
26. Nakamura Y, Yasunami Y, Hirakawa E et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulatory [abstract 462]. Transplantation 2002; 74: 160.
27. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693.
28. IDEC press release, June 10, 2002.
29. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.
30. Boon L, Laman JD, Ortiz-Buijsse A et al. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 2002; 174: 53-65.
31. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125-1127.
32. Isobe M, Suzuki J, Yamazaki S et al. Regulation by differential development of Th1 and Th2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. Circulation 1997; 96: 2247-2253.
33. Corbascio M, Ekstrand H, Osterholm C et al. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl Immunol 2002; 10: 55-61.
34. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665-674.
35. Dedrick RL, Walicke P, Garovoy M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol 2002; 9: 181-186.
36. Vincenti F, Mendez R, Rajagopalan PR et al. A phase 1/11 trial of anti-CD11a monoclonal antibody in renal transplantation [abstract #562]. Am J Transplant 2001; 1 (Suppl. 1): 276.
37. Seville F, Vanhove B, Soullilou J-P. Mechanisms of tolerance induction: blockade of costimulation. Phil Trans R Soc London B 2001; 356: 649-657.
38. Antilfa Study Group. Prospective study of anti-cd11a antibody in prevention of delayed graft function (dgf) in recipients of high-risk renal cadaver grafts [abstract 471]. Am J Transplant 2001; 1 (Suppl. 1): 253.
39. Suzuki J, Isobe M, Izawa A et al. Differential Th1 and Th2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM-1/LFA-1 and VCAM-1/VLA-4. Transpl Immunol 1999; 7: 65-72.
40. Hori J, Isobe M, Yamagami S, Tsuru T. Acceptance of second corneal allograft by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. Transplant Proc 1998; 30: 200-201.
41. Yang H, Issekutz TB, Wright JR Jr. Prolongation of rat islet allograft survival by treatment with monoclonal antibodies against VLA-4 and LFA-1. Transplantation 1995; 60: 71-76.
42. Tubridy N, Behan PO, Capildeo R et al. The effect of anti-VLA4 integrin antibody on brain lesions activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-472.
43. Gordon FH, Hamilton MI, Donoghue S et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16: 699-705.
44. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for Active Crohn's Disease. N Engl J Med 2003; 348: 24-32.
45. Wekerle T, Blaha P, Langer F, Schmid M, Muehlbacher F. Tolerance through bone marrow transplantation with costimulation blockade. Transpl Immunol 2002; 9: 125-133.
46. Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464-469.
47. Durham MM, Bingaman AW, Adams AB et al. Administration of anti-CD40 ligand and donor bone marrow leads to hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1-4.
48. Chavin KD, Qin L, Lin J, Yagita H, Bromberg JS. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. J Immunol 1993; 151:7249-7259.
49. Woodward JE, Qin L, Chavin KD et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Transplantation 1996; 62: 1011-1018.
50. Besse T, Malaise J, Mourad M et al. Prevention of rejection with BTI-322 after renal transplantation (results at 9 months). Transplant Proc 1997; 29: 2425-2426.
51. Przepiorka D, Phillips GL, Ratanatharathorn V et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998; 92: 4066-4071.
52. Dehoux JP, Talpe S, Dewolf N et al. Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody. Transplantation 2000; 69: 2622-2633.
53. Ellis N, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.
54. Sultan P, Schechner JS, McNiff JM et al. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol 1998; 15: 759-762.
55. Kaplon RJ, Hochman PS, Michler RE et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996; 61: 356-363.
56. Waldman H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? A Review. Immunol 1998; 16: 619-644.
57. Van der Lubbe PA, Reiter C, Breedveld FC et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheumatism 1993; 36: 1375.
58. Honey K, Cobbold SP, Waldmann H. Dominant tolerance and linked suppression induced by therapeutic antibodies do not depend on Fas-FasL interactions. Transplantation 2001; 69: 1683-1689.
59. Kohlhaw K, Sack U, Lehmann I et al. The monoclonal anti-CD4 antibody RIB5/2 induces donor-specific tolerance in the high-responder liver transplant model in the rat. Transplant Proc 2001; 33: 2371-2373.
60. Guo Z, Wu T, Kirchhof N et al. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection. Transplantation 2001; 71: 1656-1665.
61. Thiel MA, Takano T, Hawksworth N, Coster DJ, Williams KA. Low-dose, short-term treatment with anti-CD4 monoclonal anti-body prolongs corneal allograft survival. Transplant Proc 2001; 33: 635-636.
62. Newman R, Hariharan K, Reff M et al. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4 (+) T cells in chimpanzees. Clin Immunol 2001; 98: 164-174.
63. Genmab press release, September 24, 2002.
64. Genmab press release, September 19, 2002.
65. Winsor-Hines D, Cobbold SP, Merrill CJ et al. Induction of durable, antigen specific tolerance in primates with a short therapeutic course of non-depleting anti-cd4 antibody [abstract 254]. 2nd Annual Meeting of the Federation of Clinical Immunology Societies, San Francisco, CA.
66. Woodle ES, Xu D, Zivin RA et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999; 68: 608-616.
67. Hering BJ, Kandaswamy R, Harmon JV et al. Insulin independence after single-donor islet transplantation in type 1 diabetes with hOKT3gamma1 (Ala-Ala), sirolimus, and tacrolimus therapy. Am J Transplant 2001; 1 (Suppl. 1): 180A.
68. Norman DJ, Vincenti F, de Mattos AM et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000; 70: 1707-1712.
69. Trajkovic V. Nuvion protein design laboratories. Curr Opin Invest Drugs 2002; 3: 411-414.
70. Friend PJ, Hale G, Chatenoud L et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999; 68: 1632-1637.
71. Thomas JM, Eckhoff DE, Contreras JL et al. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: absence of chronic allograft nephropathy. Transplantation 2000; 69: 2497-2503.
72. Thompson J, Stavrou S, Weetall M et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng 2001; 14: 1035-1041.
73. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-1702.
74. Knechtle SJ, Pirsch JD, Becker BN et al. A pilot study of Campath-1H induction plus rapamycin monotherapy in renal transplantation [abstract 45]. Transplantation 2002; 74: 32.
75. Kirk AD, Hale DA, Hoffmann SC et al. Results from a human tolerance trial using campath-1h with and without infliximab [abstract 47]. Transplantation 2002; 74: 33.
76. Daller A, Woodside KJ, Meng T, Hu M, Gugliuzza KK, Hunter GC. Altered lymphocyte expression of fas and bcl-2 in renal transplant patients receiving induction therapy [abstract 3010]. Transplantation 2002; 74: 594.
77. Swanson SJ, Hale DA, Mannon RB, Harlan DM, Kleiner DE, Kirk AD. Sirolimus monotherapy in kidney transplantation following high dose thymoglobulin induction [abstract 13]. Transplantation 2002; 74: 22.
78. Corry R, Potdar S, Shapiro R et al. Pancreas and kidney-pancreas transplantation under a tolerogenic regimen of preconditioning with thymoglobulin and post-transplant tacrolimus [abstract 85]. Transplantation 2002; 74: 46.
79. Harris C, Bond G, Janson D et al. Thymoglobulin (rATG) single high dose pretreatment for human intestinal transplantation: lymphocyte depletion, drug levels and immune reconstitution [abstract 590]. Transplantation 2002; 74: 199.
80. Shapiro R, Scantlebury VP, Jordan ML et al. Kidney transplantation under a tolerogenic regimen of thymoglobulin preconditioning and post-transplant tacrolimus monotherapy [abstract 3343]. Transplantation 2002; 74: 673.
81. Abu-Elmagd KM, Bond GJ, Murase N et al. Tolerance for human intestinal transplantation [abstract 61]. Transplantation 2002; 74: 38.
82. Abu-Elmagd M, Bond G, Murase N et al. Graft immunomodulation and tolerance enhancing strategy for intestinal transplantation [abstract 640]. Transplantation 2002; 74: 218.
83. Fabre JW, Williams AF. Quantitative serological analysis of a rabbit anti-rat lymphocyte serum and preliminary biochemical characterisation of the major antigen recognised. Transplantation 1977; 23: 349-359.
84. Warr GW, Marchalonis JJ. Glycoproteins of murine thymocyte and splenocyte surface membranes; binding to concanavalin A and recognition by heterologous antilymphocyte serum. Immunochemistry 1976; 13: 753-758.
85. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51: 669-673.
86. Luke PPW, O'Brien CA, Jevnikar AM, Zhong R. Anti-CD45RB: Monoclonal antibody-mediated transplantation tolerance. Curr Mol Med 2001; 1: 533-543.
87. Rothstein DM, Livak MF, Kishimoto K et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166: 322-329.